Eli Lilly, Compounders and drug Zepbound
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down on off-brand versions. Eli Lilly announced in a press release last week ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback